Carl H. June, MD, FAACR, Honored with 2023 AACR Award for Lifetime Achievement in Cancer Research
PHILADELPHIA – The American Association for Cancer Research (AACR) will award Carl H. June, MD, Fellow of the AACR...
Search/Filter
Loading...
Clonal Hematopoiesis May Be More Common Among Pediatric Cancer Survivors Than the General Population
Researchers identified mutational signatures characteristic of chemotherapy exposure PHILADELPHIA – Researchers identified a higher rate of clonal hematopoiesis (CH)...
AACR Statement on State of the Union Address
American Association for Cancer Research (AACR) President Lisa M. Coussens, PhD, FAACR, issued the following statement on President Biden’s...
AACR and AORTIC Announce Four Grants to Support Early-career Cancer Researchers in Africa
PHILADELPHIA — The American Association for Cancer Research (AACR) and the African Organisation for Research and Training in Cancer...
An Investigational T-cell Therapy Shows Promise Against Six Viral Infections Common After Stem Cell Transplants
Responses to the off-the-shelf therapy were observed in 95 percent of patients PHILADELPHIA – Posoleucel, an investigational allogeneic off-the-shelf...
Andrea Schietinger, PhD, to Present 2023 AACR-Irving Weinstein Foundation Distinguished Lecture
PHILADELPHIA — The American Association for Cancer Research (AACR) will award the 19th AACR-Irving Weinstein Foundation Distinguished Lectureship to...
Genetic Profiling May Identify Patients with Breast Cancer Who Can Safely Omit Radiation Therapy After Breast-conserving Surgery
SAN ANTONIO – Patients with invasive breast cancer who had low scores on an investigational gene molecular signature had...
Breast-conserving Therapy May be a Treatment Option for Some Patients with Multiple Breast Lesions
SAN ANTONIO – Patients with multiple tumors in the same breast who underwent a lumpectomy followed by radiation therapy...
Camizestrant May Be Superior to Fulvestrant in Patients With Hormone Receptor-positive, HER2-negative Breast Cancer
SAN ANTONIO – The next-generation selective estrogen receptor degrader (SERD) camizestrant improved progression-free survival, compared with fulvestrant (Faslodex), in...
Adding Capivasertib to Fulvestrant Improves Progression-free Survival in Patients With Advanced Hormone Receptor-positive Breast Cancer
SAN ANTONIO – In patients with hormone receptor (HR)-positive, HER2-negative tumors resistant to aromatase inhibitors, addition of the investigational...